Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 27, 2020

View Archived Issues

IND clearance paves way for phase II study of BXCL-501 for agitation associated with delirium

Phase II study of SHR-0302 in atopic dermatitis meets primary and secondary endpoints

Crinetics presents phase II data from ACROBAT Edge and ACROBAT Evolve studies of paltusotine

ADXS-503 shows pronounced and sustained tumor control in ongoing phase I/II study in NSCLC

CohBar presents promising preclinical data for its antifibrotic CB5138 analogue peptides

Olema and Novartis to evaluate OP-1250 in combination therapies

NOI initiates phase IIb/IIIa trial of first oral systemic NO-based therapeutic for COVID-19

Shanghai Ringene Biopharma describes new STAT3 inhibitors

ENA 2020: Progress in cancer research can come one mouse at a time, study suggests

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent anti-claudin 18.2 antibodies

First cohort successfully completed in phase I study of HFB-30132A

New SGLT-1 inhibitors identified at Medshine Discovery

Shanghai Synergy Pharmaceutical Sciences, Zhejiang Huahai Pharmaceutical present BRD4 inhibitors

Prenatal treatment normalizes brain development in Down syndrome model

Dual HDAC6/VEGFR-2 inhibitors presented by Beijing Guohong Biomedical Technology

Positive interim phase II data presented for olutasidenib in AML

BioInvent receives CTA approval for first-in-human study of BI-1808 in Denmark

Ascentage cleared to begin phase Ib/II study of APG-115 for liposarcoma in China

ViralClear halts phase II study of merimepodib in hospitalized patients with COVID-19

Preclinical and clinical data presented for taminadenant + spartalizumab in cancer

GABPB1-AS1 is correlated with poor prognosis in HPV16-positive cervical cancer

APJ-specific PET radiotracer predictive of post-ischemic angiogenesis

Novel SARS-CoV-2 subunit vaccine in preclinical development

Interim data reported from phase I/II study of GTX-102 for Angelman syndrome

FDA approves IND for phase II study of VSJ-110 for allergic conjunctivitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...